Loading...
XNYS
BAX
Market cap12bUSD
Oct 08, Last price  
23.90USD
1D
-0.29%
1Q
5.66%
Jan 2017
-46.10%
Name

Baxter International Inc.

Chart & performance

D1W1MN
XNYS:BAX chart
P/E
—
P/S
1.10
EPS
—
Div yield, %
2.18%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
-0.75%
Revenues
11.24b
+5.72%
10,378,000,00011,263,000,00012,348,000,00012,562,000,00012,843,000,00013,893,000,00013,936,000,0009,413,000,00010,719,000,0009,968,000,00010,163,000,00010,584,000,00011,099,000,00011,362,000,00011,673,000,00012,146,000,00010,057,000,00010,360,000,00010,636,000,00011,244,000,000
Net income
-957m
L+47.46%
1,396,000,0001,707,000,0002,014,000,0002,205,000,0001,420,000,0002,224,000,0002,326,000,0002,012,000,0002,497,000,000968,000,0004,965,000,000602,000,0001,546,000,0001,001,000,0001,102,000,0001,284,000,000-2,433,000,0002,656,000,000-649,000,000-957,000,000
CFO
845m
-17.08%
2,183,000,0002,305,000,0002,515,000,0002,909,000,0003,003,000,0002,817,000,0003,106,000,0003,198,000,0003,215,000,0001,771,000,0001,654,000,0001,714,000,0002,017,000,0002,104,000,0001,868,000,0002,222,000,0001,211,000,0001,726,000,0001,019,000,000845,000,000
Dividend
Aug 28, 20260.01 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Baxter International Inc. is a global healthcare company that develops and supplies a broad spectrum of medical products and services through its various subsidiaries. The company's offerings encompass vital areas such as kidney care, including peritoneal and hemodialysis solutions, along with related therapies and services. It provides essential intravenous (IV) solutions, infusion pumps, administration sets, and drug reconstitution devices. Additionally, Baxter supports hospital pharmacies with premixed and oncology drug formulations, inhaled anesthetics, critical care products, and compounding services. For surgical procedures, Baxter manufactures biological products and medical devices designed to facilitate hemostasis, tissue sealing, and adhesion prevention. It also specializes in intensive care unit (ICU) treatments like continuous renal replacement and other organ support therapies. The company's portfolio extends to integrated connected care solutions, featuring advanced devices, software, communication tools, and integration technologies. Furthermore, Baxter delivers comprehensive patient monitoring and diagnostic tools for detecting, treating, and managing a wide range of illnesses, including respiratory, cardiac, vision, and physical assessment needs, as well as providing specialized surgical suite equipment like video systems, operating tables, and precision positioning devices. Beyond its own products, Baxter offers contract manufacturing and development services to pharmaceutical and biopharmaceutical partners. These diverse products and services are utilized across numerous healthcare settings, from hospitals, kidney dialysis centers, nursing homes, and rehabilitation facilities to doctors' offices and directly by patients at home under medical supervision. Baxter markets its offerings in approximately 100 countries, leveraging a direct sales force, independent distributors, drug wholesalers, and specialized pharmacy or alternative site channels. Established in 1931 and headquartered in Deerfield, Illinois, the company also has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.

Related entities

Subsidiaries (9)
Baxter AG
BAXTER HEALTHCARE LIMITED
Baxter Healthcare SA
BAXTER INNOVATIONS AND BUSINESS SOLUTIONS PRIVATE LIMITED
BAXTER PHARMACEUTICAL (ASIA) PTE. LTD.
BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED
BAXTER (MALTA) TRADING COMPANY LIMITED
Gambro Lundia AB

Key people

Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies · since 2025
James Borzi
Executive Vice President and Chief Supply Chain Officer · since 2023
Joel Grade
Chief Financial Officer, Executive Vice President · since 2025
Jeanne Mason
Chief Human Resources Officer, Executive Vice President · since 2023
Reazur Rasul
Executive Vice President, Group President - Healthcare Systems and Technologies · since 2023
David Rosenbloom
Executive Vice President, General Counsel · since 2023
Alok Sonig
Executive Vice President, Group President - Pharmaceuticals · since 2023
Lead Independent Director · since 2025
D. Brent Shafer
Chairman of the Board, Interim Chief Executive Officer · since 2025
William Ampofo
Independent Director · since 2023
Independent Director · since 2024
Independent Director · since 2019
Independent Director · since 2019
Stephen Oesterle
Independent Director · since 2017
David Wilkes
Independent Director · since 2021
IPO date
May 15, 1961
Employees
60,000
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
1 BAXTER PARKWAY
DEERFIELD, IL 60015
US
Trading name
BAXTER TRAVENOL LABORATORIES INC

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT